HSP-130
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-metastatic Breast Cancer
Conditions
Non-metastatic Breast Cancer
Trial Timeline
Dec 1, 2015 → Oct 1, 2017
NCT ID
NCT02650193About HSP-130
HSP-130 is a phase 2 stage product being developed by Pfizer for Non-metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02650193. Target conditions include Non-metastatic Breast Cancer.
What happened to similar drugs?
1 of 6 similar drugs in Non-metastatic Breast Cancer were approved
Approved (1) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02650193 | Phase 2 | Completed |
Competing Products
14 competing products in Non-metastatic Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Bicalutamide + Placebo | AstraZeneca | Phase 3 | 40 |
| Gefitinib, radiotherapy | AstraZeneca | Phase 1/2 | 32 |
| Bicalutamide + Placebo | AstraZeneca | Phase 3 | 40 |
| Gefitinib, 5-fluorouracil, leucovorin and radiotherapy | AstraZeneca | Phase 1/2 | 24 |
| Bicalutamide + Placebo | AstraZeneca | Phase 3 | 40 |
| Avelumab | Merck | Phase 2 | 35 |
| Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigator | Novartis | Phase 3 | 47 |
| AK104 + Lenvatinib | Akeso | Phase 2 | 39 |
| Darolutamide (Nubeqa, BAY1841788) | Bayer | Pre-clinical | 30 |
| Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + Apalutamide | Bayer | Pre-clinical | 23 |
| Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + Apalutamide | Bayer | Pre-clinical | 23 |
| Darolutamide (Nubeqa, BAY1841788) + Placebo | Bayer | Phase 3 | 37 |
| Darolutamide (Nubeqa, BAY1841788) | Bayer | Approved | 47 |
| Apalutamide + Darolutamide (BAY 1841788) + Enzalutamide | Bayer | Pre-clinical | 23 |